Contrasting Amedica (AMDA) & Its Peers
Amedica (NASDAQ: AMDA) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its peers? We will compare Amedica to similar businesses based on the strength of its profitability, valuation, risk, earnings, institutional ownership, analyst recommendations and dividends.
Insider & Institutional Ownership
63.6% of Amedica shares are owned by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 0.1% of Amedica shares are owned by company insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Amedica has a beta of -2.08, indicating that its share price is 308% less volatile than the S&P 500. Comparatively, Amedica’s peers have a beta of 0.47, indicating that their average share price is 53% less volatile than the S&P 500.
This is a breakdown of current ratings for Amedica and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Amedica currently has a consensus price target of $60.00, suggesting a potential upside of 1,933.90%. As a group, “Medical Devices & Implants” companies have a potential upside of 35.91%. Given Amedica’s higher probable upside, analysts plainly believe Amedica is more favorable than its peers.
This table compares Amedica and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Amedica and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Amedica||$15.23 million||-$16.59 million||-0.72|
|Amedica Competitors||$1.67 billion||$207.58 million||71.92|
Amedica’s peers have higher revenue and earnings than Amedica. Amedica is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Amedica peers beat Amedica on 8 of the 12 factors compared.
Amedica Company Profile
Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States, Europe and Brazil for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride-based spinal fusion products, it markets a line of non-silicon nitride spinal surgery products, which allows the Company to provide surgeons and hospitals with a solution for spinal procedures. Its Valeo interbody spinal fusion devices include Anterior Lumbar, Posterior Lumbar, Oblique Lumbar, Transforaminal Lumbar, Lateral Lumbar, Cervical and Corpectomy.
Receive News & Ratings for Amedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica and related companies with MarketBeat.com's FREE daily email newsletter.